Abstract:
The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or ameliorating the symptoms of T cell mediated inflammatory and autoimmune disorders, including hepatic disorders, which comprise administering to a subject in need thereof a composition comprising as an active ingredient an effective quantity of a molecule selected from: HSP60, p277, fragments, analogs, homologs and derivatives thereof, and nucleic acids encoding same. Also disclosed are T cell vaccination methods for treating or preventing T cell mediated disorders.
Abstract:
PROBLEM TO BE SOLVED: To provide an optical method for detecting Alzheimer disease.SOLUTION: The main subject of the present invention relates to a non-invasive optical imaging method for monitoring an initial pathological event (e.g., generation of amyloid plaque, the amount and position thereof) specific to Alzheimer disease (AD). The capability of monitoring such an event provides a basis for AD diagnosis, prognosis prediction and potential therapy evaluation, above all. Further, the main subject of the present invention is to introduce a new method for treating AD and a retinal disease related with AD. Aβ plaque detection is extremely limited particularly in terms of high resolution. Therefore, the present invention is based on a study focusing on an eye, as alternative means of a tissue from the brain, which can be directly, repeatedly and non-invasively imaged.
Abstract:
Described herein are compounds having Formula I or Formula II: wherein each dashed line independently represents a saturated or unsaturated bond; R1 and R′1 are aryl or heteroaryl as defined herein; and R2 and R′2 are as defined herein. Further described is a method of inhibiting nuclear translocation of ERK1/2 in a cell, by contacting the cell with a compound having Formula I or Formula II. The compounds may also be for use in treating a disease or disorder associated with nuclear translocation of ERK1/2.
Abstract:
Disclosed are methods of treating diseases or disorders mediated by dysregulated CDK4/6 and/or Pin 1 activity comprising co-administering a therapeutically effective amount of one or more CDK4/6 inhibitors, and a therapeutically effective amount of one or more Pin1 inhibitors, or a pharmaceutically acceptable salt or salts thereof
Abstract:
A system and method for detecting at least one cardiac anomaly includes a specifically configured computer hardware arrangement configured to receive ultrasound imaging information related to a heart of a patient and to use at least one neural network trained on multiple recognition and analysis procedures to detect at least one anomaly and/or to classify a severity of at least one anomaly.
Abstract:
Provided herein is a method for obtaining a humanized antibody based on a non-human antibody having an affinity to an antigen of interest, that starts from an experimental or model structure, grafts the non-human CDRs on a library of human frameworks and uses restrained/constrained atomistic simulations to relax and rank the designs by energy.
Abstract:
The present invention provides humanized monoclonal antibodies that specifically recognize human QSOX1 and inhibit its activity. The humanized antibodies of the present invention were designed following in-silico selection of specific variable region segments, based on their energy scores, and were produced and confirmed to function properly in binding and inhibiting human QSOX1. The present invention further provides pharmaceutical compositions comprising the humanized antibodies and methods for their use in cancer therapy and diagnosis.